Galena’s NeuVax Breast Cancer Vaccine Administered to First Patient

Galena’s NeuVax Breast Cancer Vaccine Administered to First Patient
shutterstock_156671135The first patient has been treated in the Galena Biopharam, Inc. phase 2 clinical trial addressing patients with high risk HER2 3+ and/or HER2 gene-amplified breast cancer. Treatment consists of Galena's new NeuVax (nelipepimut-S) breast cancer vaccine along with granulocyte macrophage-colony stimulating factor (GM-CSF) and Genentech's Herceptin (trastuzumab). "I believe that NeuVax and Herceptin are complementary to one another, and the combination of these agents may provide clinical benefit to these patients," said Elizabeth A. Mittendorf, MD, PhD, in a news release from Galena. Dr. Mittendorf is from the University of Texas MD Anderson Cancer Center and is overseeing the trial. Patients enrolled in the trial, which are expected to number 100, have HER2 3+ breast cancer, as defined by immunohistochemistry, or HER2 gene-amplified breast cancer, as defined by fluorescence in situ hybridization (FISH) >2.0, with either HLA A2+ or HLA A3+ status. These patients are especially susceptible to recurrence and make up approxim
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.